PIVI’s Work with NITAGs
What is a NITAG and why are they important?
National Immunization Technical Advisory Groups (NITAGs) are groups of national experts who use evidence-based methods to develop recommendations on vaccines and immunization for policy-makers and program managers. They consider both global information and local epidemiological and social contexts to empower decision-makers to make credible policy decisions, which are crucial for securing government funding and public acceptance for new vaccines.
Strong and functioning NITAGs are a critical component in moving countries from evidence to action – and on to implementing effective data-driven vaccine programs.
PIVI has supported NITAG strengthening since 2017 – working with partners such as CDC , WHO, and the Global NITAG Network to:
- Provide training to new NITAGs,
- Developing tools to support the development of evidence-based recommendations for vaccine-preventable diseases
- Providing training and technical support to country NITAGs to develop recommendations for seasonal influenza vaccination.
PIVI continues to offer support to NITAGs by providing several types of support, including:
- Toolkits for facilitated training and self-learning in the Evidence to Recommendations process;
- Tools for assessment of NITAG maturity (NITAG Maturity Assessment tool – NMAT);
- Working with partners like CDC, WHO HQ and Regional offices, GNN and NITAG Support Hub (NISH) to provide facilitated training and continued technical support to develop vaccine recommendations for influenza and other diseases.
PIVI and The Task Force for Global Health are a partner institution of the Global NITAG Network (GNN). The GNN Resource Center is where NITAGs can go for up to date information and materials for evidence based decision making.
Monkeypox Evidence Brief
The Monkeypox Evidence Brief for NITAGS was jointly produced by PIVI at The Task Force for Global Health, and the U.S. Centers for Disease Control and Prevention.
This evidence brief was produced in response to the multi-country outbreak in Africa, but can be used by NITAGs globally to inform their decision-making regarding which monkeypox vaccine to choose and when or how to select a target population.
Each section includes specific references, scientific articles, and resources for NITAGs to consider for the topic. The end of the evidence brief includes references organized by topic for NITAGs to consider when gathering evidence to make recommendations.
This document can serve as a starting point for NITAGs to develop context-specific recommendations in their countries.
The vaccines considered in this document are:
1. MVA-BN
2. LC16m8
3. ACAM2000
Request Access to Edit Documents
Fill out the form below to request access to edit documents and we will get back to you as soon as possible.